Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing PlanInvestors Business Daily • 01/12/26
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial TransitionGlobeNewsWire • 01/11/26
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?Zacks Investment Research • 12/31/25
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/18/25
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/06/25
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On GoalSeeking Alpha • 12/04/25
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?Zacks Investment Research • 12/04/25
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare ConferenceGlobeNewsWire • 11/12/25
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/04/25
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewsWire • 11/04/25
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/03/25
Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/29/25
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/28/25
Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 10/20/25
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a BetZacks Investment Research • 10/17/25
Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/17/25
Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)Seeking Alpha • 09/09/25
Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/09/25
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/04/25
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?Zacks Investment Research • 08/28/25
Beam Therapeutics to Participate in Upcoming September 2025 Investor ConferencesGlobeNewsWire • 08/25/25
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 08/14/25